Eupraxia Pharmaceuticals Inc (EPRX : TSX)
Common Stock
$9.38
CAD
+0.32 (3.53%)
Last updated: 2026-06-22
EPRX
Eupraxia Pharmaceuticals Inc
WealthAwesomePerformance
1 Day
+3.53%
1 Week
+7.57%
1 Month
-3.30%
YTD
-10.33%
Key Statistics
Market Cap
$591.86M
52W High
$12.86
52W Low
$5.89
P/E Ratio
-
50 Day MA
$9.59
200 Day MA
$9.57
Beta
1.48
Dividend Yield
-
Technical Indicators
Price vs 50-Day SMA
Price vs 200-Day SMA
Recent Price History
| Date | Open | High | Low | Close | Adj Close | Volume |
|---|---|---|---|---|---|---|
| 6/22/2026 | $9.00 | $9.43 | $8.92 | $9.38 | $9.38 | 103,752 |
| 6/19/2026 | $9.12 | $9.12 | $8.89 | $9.06 | $9.06 | 21,287 |
| 6/18/2026 | $9.05 | $9.18 | $8.87 | $9.17 | $9.17 | 69,626 |
| 6/17/2026 | $8.23 | $9.04 | $8.23 | $8.82 | $8.82 | 60,179 |
| 6/16/2026 | $8.89 | $8.89 | $7.85 | $8.42 | $8.42 | 88,292 |
| 6/15/2026 | $8.51 | $8.77 | $8.51 | $8.72 | $8.72 | 26,375 |
| 6/12/2026 | $8.54 | $8.61 | $8.37 | $8.45 | $8.45 | 11,075 |
| 6/11/2026 | $8.24 | $8.47 | $8.24 | $8.42 | $8.42 | 16,738 |
| 6/10/2026 | $8.40 | $8.52 | $8.18 | $8.27 | $8.27 | 34,847 |
| 6/9/2026 | $8.46 | $8.65 | $8.21 | $8.34 | $8.34 | 67,885 |
Analyst Price Targets
Based on analyst covering EPRX
Wall Street analysts forecast EPRX stock price to rise 70.6% over the next 12 months.
Consensus
No RatingAvg. Target
C$16.00
+70.6% Upside
Current Price
C$9.38
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on EPRX's historical volatility
30-Day Vol
65.6%
Annualized
90-Day Vol
53.9%
Annualized
Trend (90d)
-2.7%
Annualized drift
90d Mean
C$9.29
Expected price
| Horizon | Expected | 68% Range (1ฯ) |
|---|---|---|
| 30 trading days | C$9.35 | C$7.46 โ C$11.72 |
| 60 trading days | C$9.32 | C$6.77 โ C$12.84 |
| 90 trading days | C$9.29 | C$6.28 โ C$13.75 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ยฑ1ฯ, 95% band = ยฑ2ฯ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
About Eupraxia Pharmaceuticals Inc
Eupraxia Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on the development of products to address therapeutic areas with unmet medical need. Its proprietary Diffusphere technology optimizes drug delivery for applications with significant unmet medical need. The company's product portfolio includes EP-104IAR, which is in Phase III clinical trial for the treatment of knee osteoarthritis; EP-104GI that is in Phase II clinical trial for treating eosinophilic esophagitis; and EP-104, which is under preclinical studies for the treatment of gastrointestinal tract, such as eosinophilic esophagitis. The company was formerly known as Plaza Capital Partners Inc. and changed its name to Eupraxia Pharmaceuticals Inc. in May 2012. Eupraxia Pharmaceuticals Inc. was incorporated in 2011 and is headquartered in Victoria, Canada.
Financials
- Revenue (TTM)
- $0
- EBITDA
- $-47.07M
- Profit Margin
- 0.00%
- ROE (TTM)
- -54.52%
- EPS (Diluted)
- -1.48
- Book Value
- 2.45
Classification
- Sector
- Health Care
- Industry
- Biotechnology
- Group
- Pharmaceuticals, Biotechnology & Life Sciences
Advertisement
7 stocks to buy and hold forever
Blue-chip dividend stocks for long-term wealth building.
Get the FREE ReportExplore More
Common Questions About EPRX
Articles Featuring EPRX.TO
Latest articles and analysis covering EPRX.TO
Why Eupraxia Pharmaceuticals Inc stock is rising today
Eupraxia Pharmaceuticals Inc. has seen its stock rise by 3.53% following a successful Annual General Meeting, where shareholders expressed strong support for the board of directors. This reflects growing confidence in the company's innovative approaches to drug delivery.
Why Eupraxia Pharmaceuticals Inc stock is sliding today
Eupraxia Pharmaceuticals Inc's stock has seen a 3.05% decline today, closing at CA$8.89. Investors are expressing caution as the company navigates its clinical development phase amidst recent public offerings.
Why Eupraxia Pharmaceuticals Inc stock is rising today
Eupraxia Pharmaceuticals Inc has seen a 3.97% rise in its stock price, closing at CA$9.17. This uptick is indicative of investor confidence, bolstered by the company's financial strength and promising clinical developments.
Why Eupraxia Pharmaceuticals Inc stock is skyrocketing today
Eupraxia Pharmaceuticals Inc has experienced a significant stock increase of 5.70% today, driven by its robust financial position and ongoing clinical developments. As the company continues to innovate in the biotech space, investors are keenly watching its progress.
Why Eupraxia Pharmaceuticals Inc stock is plummeting today
Eupraxia Pharmaceuticals Inc's stock fell sharply today, closing at CA$8.22, down 5.73%. Investors are left questioning the company's stability amidst a lack of recent news.
